{
    "nct_id": "NCT02932956",
    "official_title": "Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells as Immunotherapy for Patients With Pediatric Solid Tumors",
    "inclusion_criteria": "* Relapsed or refractory GPC3-positive* solid tumors (currently only enrolling liver tumors)\n* Age ≥ 1 year and ≤ 21 years\n* Lansky or Karnofsky score ≥60%\n* Life expectancy ≥16 weeks\n* Child-Pugh-Turcotte score <7 (for patients with hepatocellular carcinoma only)\n* Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent\nHealthy volunteers allowed\nMust have minimum age of 1 Year\nMust have maximum age of 21 Years",
    "exclusion_criteria": "* History of hypersensitivity reactions to murine protein-containing products OR presence of human anti-mouse antibody (HAMA) prior to enrollment (only patients who have received prior therapy with murine antibodies)\n* History of organ transplantation\n* Known HIV positivity\n* Active bacterial, fungal or viral infection (except Hepatitis B or Hepatitis C virus infections)\n* Severe previous toxicity from cyclophosphamide or fludarabine\n\nTreatment Eligibility\n\nInclusion Criteria:\n\n* Age ≥ 1 year and ≤ 21 years\n* Barcelona Clinic Liver Cancer Stage A, B or C (for patients with hepatocellular carcinoma only)\n* Life expectancy of ≥ 12 weeks\n* Lansky or Karnofsky score ≥ 60%\n* Child-Pugh-Turcotte score < 7 (for patients with hepatocellular carcinoma only)\n* Adequate organ function:\n\n  * Creatinine clearance as estimated by Cockcroft Gault or Schwartz ≥ 60 ml/min\n  * serum AST< 5 times ULN\n  * total bilirubin < 3 times ULN for age\n  * INR ≤1.7 (for patients with hepatocellular carcinoma only)\n  * absolute neutrophil count > 500/microliter\n  * platelet count > 25,000/microliter (can be transfused)\n  * Hgb ≥7.0 g/dl (can be transfused)\n  * pulse oximetry >90% on room air\n* Recovered from acute toxic effects of all prior chemotherapy and investigational agents before entering this study\n* Sexually active patients must be willing to utilize one of the more effective birth control methods for 3 months after the T-cell infusion.\n* Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent\n\nExclusion Criteria\n\n* Pregnancy or lactation\n* Uncontrolled infection\n* Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day, dose adjustment or discontinuation of medication must occur at least 24 hours prior to CAR T cell infusion)\n* Known HIV positivity\n* Active bacterial, fungal or viral infection (except Hepatitis B or Hepatitis C virus infections)\n* History of organ transplantation\n* History of hypersensitivity reactions to murine protein-containing products OR presence of human anti-mouse antibody (HAMA) prior to enrollment (only patients who have received prior therapy with murine antibodies)\n* Severe previous toxicity from cyclophosphamide or fludarabine\n\nGPC3 expression will be evaluated by standard immunohistochemistry (IHC). A tumor is considered GPC3 positive, when the staining is Grade 2 (>25% positive tumor cells) or above with an intensity score of 2 or above on a scale of 0 to 4.",
    "miscellaneous_criteria": "Procurement Eligibility"
}